Announcements Trials
Browse Landscape

Phase

Phase 1/2 4Phase 1 2Phase 2 1

Status

Completed 13Terminated 7Recruiting 5Unknown 4Withdrawn 2Active not recruiting 1

Sponsor Class

INDUSTRY 6OTHER 1

Study Type

Interventional 7

Sponsor

Cancer Type

Gastrointestinal 69Head & Neck 43Thoracic 12Tumor-Agnostic 7CNS 5Gynecologic 4Breast 3Sarcoma 2Other solid neoplasm 2Genitourinary 2Plasma cell 1Myeloid 1Lymphoid 1Dermatologic 1

Conditions

Neoplasms 6Neoplasm Metastasis 2Carcinoma, Squamous Cell 1

Interventions

Gemcitabine 13pembrolizumab 12Capecitabine 9Irinotecan 8Erlotinib Hydrochloride 8Carboplatin 8Blood Specimen Collection 8Nivolumab 7Docetaxel 7Cisplatin 7Cetuximab 7Paclitaxel 6Everolimus 6130-nm albumin-bound paclitaxel 6vadimezan 5Magnetic Resonance Spectroscopy 5Fluorouracil 5Cyclophosphamide 5trametinib 4Leucovorin 4Lapatinib 4Ipilimumab 4Bevacizumab 4Albumin-Bound Paclitaxel 4temsirolimus 3atezolizumab 3abemaciclib 3Trastuzumab 3Radiotherapy 3Radiation 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Terminated × Cetuximab × Tumor-Agnostic × Clear all
NCT04009681 2025-12-15

HAMMER

Synthorx, Inc, a Sanofi company

Phase 1/2 Terminated
175 enrolled
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT04717375 2025-08-07

Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors

Sanofi

Phase 1/2 Terminated
125 enrolled
Tumor-Agnostic

Neoplasms

NCT03783403 2024-09-19

A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Participants With Advanced Solid and Hematologic Cancers

Celgene

Phase 1 Terminated
206 enrolled
Tumor-Agnostic

Neoplasms

NCT03387111 2024-08-05

QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed

ImmunityBio, Inc.

Phase 1/2 Terminated
4 enrolled 14 charts
Tumor-Agnostic

Carcinoma, Squamous Cell

NCT00954512 2018-08-24

Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)

Merck Sharp & Dohme LLC

Phase 1/2 Terminated
15 enrolled 11 charts
Tumor-Agnostic

Neoplasms

NCT02316496 2017-08-01

REGAIN

GERCOR - Multidisciplinary Oncology Cooperative Group

Phase 2 Terminated
2 enrolled
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT00811993 2016-11-02

A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid Tumors

Hoffmann-La Roche

Phase 1 Terminated
104 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡